Core Viewpoint - The company is optimizing its capacity allocation and management efficiency by adjusting the business operations of its subsidiary, Shenzhen Yinos Bio-pharmaceutical Safety Evaluation Research Institute Co., Ltd, which will no longer undertake new business except for existing operations [1] Financial Summary - Shenzhen Yinos was established in November 2021 with a registered capital of 20 million yuan [1] - As of 2024, the total assets of the company were 115 million yuan, with a net asset value of -64.87 million yuan, operating revenue of 65.71 million yuan, and a net profit of -21.50 million yuan [1] - By March 31, 2025, the total assets decreased to 105 million yuan, net assets further declined to -71.61 million yuan, operating revenue dropped to 14.92 million yuan, and net profit improved slightly to -6.73 million yuan [1]
益诺思：控股子公司深圳益诺思将进行业务调整